BioSante Pharmaceuticals Inc. is doubling down on its investment on LibiGel, its testosterone gel for hypoactive sexual desire disorder in menopausal women, with a decision to conduct two new Phase III trials in the face of the failure of the last two studies.
The firm believes it can design the trials to minimize the greater-than-expected placebo response that thwarted the statistical significance of LibiGel efficacy in two previous studies, President and CEO Stephen...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?